The present invention relates to a process for producing a fermented milk product comprising the steps of: 1) adding a starter culture of lactic acid bacteria comprising at least one lactose-deficient Streptococcus thermophilus strain, which is capable of metabolizing a non-lactose carbohydrate, and at least one lactose-deficient Lactococcus lactis strain, which is capable of metabolizing the non-lactose carbohydrate, to a milk base, and 2) fermenting the milk for a period of time until a target pH is reached to obtain a fermented milk product.

An object of the present invention is to provide a novel food material effective for recovering from fatigue and/or preventing fatigue accumulation. The present invention provides a composition for use in recovering from fatigue and/or preventing fatigue accumulation, comprising a Lactococcus bacterium as an active ingredient.

An object of the present invention is to provide a novel food material effective for recovering from fatigue and/or preventing fatigue accumulation. The present invention provides a composition for use in recovering from fatigue and/or preventing fatigue accumulation, comprising a Lactococcus bacterium as an active ingredient.

The present invention relates to the use of at least one lactic acid bacterium, or a composition comprising thereof or conditioned thereby, for increasing or maintaining a Faecalibacterium prausnitzii population.

The present invention relates to the use of at least one lactic acid bacterium, or a composition comprising thereof or conditioned thereby, for increasing or maintaining a Faecalibacterium prausnitzii population.

Novel Lactococcus lactis subsp. lactis lactic acid bacterium strain having improved texturizing properties and method of using the strain for producing a food product.

The present disclosure pertains to a treatment strategy to combat select bacteria in the gut, such as H. pylori. The strategy uses a probiotic-based system to express and deliver a guided antimicrobial peptide to the gut. The guided antimicrobial peptide is expressed from a hybrid gene that codes for an antimicrobial peptide fused to a guide peptide, the latter binding to a protein of the target bacterium. This technology can eliminate the target bacterium selectively and specifically from the gut microbiota. The specificity of the targeting, being at the strain, species or genus level, depends on the sequence of the guide peptide used to provide the targeting. The treatment can be administered orally, such as by using an ingestible probiotic.

The present invention relates to the field of food industry as well as to medicine, more particularly to novel compositions comprising hydrogen peroxide (H.sub.2O.sub.2) in combination with glycolic acid, glyoxylic acid, glycine, serine or salts thereof that allow using H.sub.2O.sub.2 as antimicrobial, especially antibacterial and antiviral or signaling agent yet neutralizing the toxic effects of the latter on the cell and tissues. The present invention also relates to a food product, an alcoholic/non-alcoholic beverage, or a nutritional supplement comprising the inventive composition and a method for production thereof.

This disclosure relates to methods of using beneficial bacterial such as, a Lactococcus lactis strain, to manage, treat, or prevent obesity, fatty liver disease, harmful ionizing radiation, and other conditions or aliments. In certain embodiments, the subject is at risk or, susceptible to, exhibiting symptoms of, or diagnosed with a disease or conditions disclosed herein. In certain embodiments, methods comprise administering an effective amount of a Lactococcus lactis strain to a subject in need thereof. In certain embodiments, the Lactococcus lactis strain is Lactococcus lactis subsp. cremoris ATCC 19257 or a mutant thereof.

The disclosure discloses Lactococcus lactis subsp. lactis CCFM1018 and application thereof in preparation of food and medicine for excreting a plasticizer, and belongs to the technical field of microorganisms. The Lactococcus lactis subsp. lactis CCFM1018 not only is significantly better than the intestinal resident bacteria Escherichia coli and Enterococcus faecalis in terms of the effect of promoting the excretion of DEHP and MEHP, but also is better than the commercial strain Lactobacillus rhamnosus LGG. Therefore, the Lactococcus lactis subsp. lactis CCFM1018 of the disclosure can be used as an effective means to prevent and alleviate body damage caused by DEHP and MEHP, and does not have toxic or side effects of drugs. Lactococcus lactis subsp. lactis CCFM1018 can be used to prepare pharmaceutical compositions and fermented food for alleviating and preventing the toxicity of DEHP and metabolites thereof, and has a very broad application prospect.